SURF — Surface Oncology Share News
0.000.00%
Last trade - 00:00HealthcareAdventurousSmall Cap
- $65.08m
- $8.82m
- $30.00m
Brief: Surface Oncology To Collaborate With Roche On Immuno-Oncology Study Evaluating SRF388
Surface Oncology Inc reports results for the quarter ended in March - Earnings Summary
Brief: Surface Oncology Inc - QTRLY Total Revenue $1.6 Million Versus $38.6 Million
Brief: Surface Oncology Says Co Entered Into An Exclusive Product License Agreement With Vaccinex, Inc.
Brief: Surface Oncology Inc - Announced Promotion Of Jessica Fees To Chief Financial Officer
Brief: Surface Oncology Presents Promising Preclinical Data For Lead Immunotherapy Product Candidates
Surface Oncology surges as pancreatic cancer drug gets 'orphan' status
Brief: Surface Oncology’s SRF617 Receives Orphan Drug Designation From FDA For Treatment Of Pancreatic Cancer
U.S. STOCKS ON THE MOVE-Tesla, INVO Bioscience, Stitch Fix, GameStop
U.S. STOCKS ON THE MOVE-Tesla, GameStop, Peloton, INVO Bioscience
Brief: Surface Oncology Reports Q4 Earnings Per Share $1.56
U.S. STOCKS ON THE MOVE-GameStop, Surface Oncology, Tesla
Surface Oncology: Gains on Merck tie-up, surprise Q4 profit
Vaccinex Inc: Gains on licensing antibody to Surface Oncology
Brief: Surface Oncology To Appoint Robert Ross, M.D., As President And Chief Executive Officer
U.S. RESEARCH ROUNDUP- Accenture, Dow, Skyline Champion
Brief: Surface Oncology Announces Exclusive License Agreement With Gsk For Novel Immunotherapy Program
U.S. RESEARCH ROUNDUP-F5 Networks, Taubman Centers, Urovant Sciences
Brief: Surface Oncology Announces SRF617 And SRF388 Will Advance To Combination And Expansion Stages Of Ongoing Phase 1 Clinical Trials